Gold nanoparticle‑mediated delivery of paclitaxel and nucleic acids for cancer therapy (Review).

Content Provider	Europe PMC
Author	Wang, Zhiguang Dong, Jianyu Zhao, Qiaojiajie Ying, Ying Zhang, Lijie Zou, Junrong Zhao, Shuqi Wang, Jiuju Zhao, Yuan Jiang, Shanshan
Copyright Year	2020
Abstract	Paclitaxel is a potent antineoplastic agent, but poor solubility and resistance have limited its use. Gold nanoparticles (AuNPs) are widely studied as drug carriers because they can be engineered to prevent drug insolubility, carry nucleic acid payloads for gene therapy, target specific tumor cell lines, modulate drug release and amplify photothermal therapy. Consequently, the conjugation of paclitaxel with AuNPs to improve antiproliferative and pro-apoptotic potency may enable improved clinical outcomes. There are currently a number of different AuNPs under development, including simple drug or nucleic acid carriers and targeted AuNPs that are designed to deliver therapeutic payloads to specific cells. The current study reviewed previous research on AuNPs and the development of AuNP-based paclitaxel delivery.
ISSN	17912997
Journal	Molecular Medicine Reports
Volume Number	22
PubMed Central reference number	PMC7646735
Issue Number	6
PubMed reference number	33173972
e-ISSN	17913004
DOI	10.3892/mmr.2020.11580
Language	English
Publisher	D.A. Spandidos
Publisher Date	2020-10-11
Access Restriction	Open
Rights License	This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Copyright: © Wang et al.
Subject Keyword	paclitaxel gold nanoparticles cancer drug delivery photothermal therapy
Content Type	Text
Resource Type	Article
Subject	Genetics Molecular Biology Biochemistry Cancer Research Molecular Medicine Oncology